FDA Grants Priority Review For Amgen's BLINCYTO ® (blinatumomab) Supplemental Biologics License Application
Application Includes Overall Survival Data From Phase 3 TOWER Study to Support Conversion From Accelerated Approval to Full Approval
Acceptance Reinforces Significant Need for Innovative Treatment Options for Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy
THOUSAND OAKS, Calif., March 29, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for BLINCYTO® (blinatumomab) to include overall survival (OS) data from the Phase 3 ...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Food and Drug Administration (FDA) | Grants | Immunotherapy | Leukemia | Pharmaceuticals | Study